FWL Investment Management’s Moderna MRNA Stock Holding History

FWL Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-101	Closed	-$6.75K	–	323
2024 Q3	$6.75K	Buy	+101	New	+$9.27K	﹤0.01%	250

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

FWL Investment Management's MRNA Position: Q4 2024 in Review

FWL Investment Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 101 shares — an estimated $6.75K sold.

FWL Investment Management first reported a position in MRNA in Q3 2024 and held it in 1 quarter. The position peaked at $6.75K in Q3 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

FWL Investment Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
FWL Investment Management sold 101 Moderna shares in Q4 2024, an estimated $6.75K.
FWL Investment Management first reported a position in Moderna in Q3 2024 and held it in 1 quarter.
FWL Investment Management's Moderna position peaked at $6.75K in Q3 2024.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on FWL Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.